Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 9/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.43 |
| ▸ | FAP | Q12884 | 5/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.43 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 5/20 | 0.41 |
| ▸ | REN | P00797 | 3/20 | 0.41 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17323644 | 1.00 | GAA (0.46) | GAAHPGDDPP4DPP7FAP | |
| SCHEMBL9927075 | 1.00 | GAA (0.46) | GAAHPGDDPP4DPP7FAP | |
| SCHEMBL17323635 | 0.94 | HPGD (0.53) | GAAHPGDDPP7LMNAHSD17B10 | |
| SCHEMBL17323629 | 0.94 | HPGD (0.53) | GAAHPGDDPP7LMNAHSD17B10 | |
| SCHEMBL4546663 | 0.94 | HPGD (0.53) | GAAHPGDDPP7LMNAHSD17B10 | |
| SCHEMBL17323643 | 0.87 | PIK3CD (0.41) | GAAHPGDDPP4DPP7FAP | |
| SCHEMBL14656006 | 0.84 | DPP4 (0.62) | GAAHPGDDPP4DPP7FAP | |
| SCHEMBL15832327 | 0.84 | GAA (0.43) | GAAHPGDDPP4DPP7FAP | |
| SCHEMBL12709881 | 0.82 | DPP4 (0.46) | GAAHPGDDPP4DPP7FAP | |
| SCHEMBL13111950 | 0.81 | ACE (0.47) | DPP4DPP7FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020139988-A1 | COMPOSITIONS FOR INHIBITING UBIQUITIN SPECIFIC PROTEASE 1 | FORMA THERAPEUTICS, INC. (US) | 2020-07-02 | — | — | WO | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8268862-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRTIS PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1553089-B1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMA CO LTD (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-7541477-B2 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | BANYU PHARMACEUTICAL CO., LTD (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1553089-A1 | ANTAGONIST OF MELANIN-CONCENTRATING HORMONE RECEPTOR COMPRISING BENZIMIDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | GAA 1133/4885HPGD 335/4885DPP4 1525/4885 |
| US-20110009381-A1 | SOLUBILIZED THIAZOLOPYRIDINES | SIRT3, SIRT1, SIRT2 | GAA 443/4885HPGD 230/4885DPP4 532/4885 |
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | GAA 511/4885HPGD 316/4885DPP4 845/4885 |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GAA 1203/4885HPGD 229/4885DPP4 2284/4885 |
| US-20050222161-A1 | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient | MC1R, MCHR1, MCHR2 | GAA 477/4885HPGD 1166/4885DPP4 2411/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | GAA 511/4885HPGD 316/4885DPP4 845/4885 |
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GAA 1087/4885HPGD 233/4885DPP4 2237/4885 |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | GAA 1775/4885HPGD 442/4885DPP4 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.